Skip to search formSkip to main contentSkip to account menu

deramciclane

Known as: 2-phenyl-2-(dimethylaminoethoxy)-1,7,7-trimethylbicyclo(2.2.1)heptane hemifumarate, N,N-dimethyl-2-((1,7,7-trimethyl-2-phenylbicyclo(2.2.1)hept-2-yl)oxy)ethamine 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (5)

Anti-Anxiety AgentsAnticonvulsantsBicyclo CompoundsBornanes

Narrower (3)

EGIS 3886EGYT 3886deramciclane, (endo-EGYT 3886)-isomer

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
BIOTRANSFORMATION OF DERAMCICLANE IN PRIMARY HEPATOCYTES OF RAT, MOUSE, RABBIT, DOG, AND HUMAN
The metabolic fate of deramciclane [(1R,2S,4R)-(–)-2-phenyl-2-(2′-dimethylamino-ethoxy)-1,7,7-trimethyl-bicyclo[2.2.1]heptane], a… 
2004
2004
Effect of the novel anxiolytic drug deramciclane on cytochrome P450 2D6 activity as measured by desipramine pharmacokinetics
BackgroundIn vitro findings have indicated that the novel anxiolytic drug, deramciclane, is an inhibitor of the cytochrome P450… 
2003
2003
Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone
RationalePreliminary in vitro findings indicated that the novel anxiolytic drug, deramciclane is a substrate for the cytochrome… 
2001
2001
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze
Abstract. Objective: To investigate whether a 5-hydroxytryptamine (5-HT) reuptake inhibitor (paroxetine) has an anxiogenic-like… 
2000
2000
Oral, Intraperitoneal and Intravenous Pharmacokinetics of Deramciclane and its N‐desmethyl Metabolite in the Rat
The pharmacokinetic properties of deramciclane fumarate (EGIS‐3886), a new potential anxiolitic agent, and its N‐desmethyl… 
1999
1999
Differential EEG effects of the anxiolytic drugs, deramciclane (EGIS-3886), ritanserin and chlordiazepoxide in rats
Abstract The influence of serotonergic and benzodiazepine type anxiolytic drugs on the cortical activation and sleep-wakefulness… 
1999
1999
Application of overpressured layer chromatography combined with digital autoradiography and mass spectrometry in the study of deramciclane metabolism.
Overpressured layer chromatography was combined with the highly sensitive and rapid digital autoradiography (DAR) and mass… 
1999
1999
The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers
The pharmacokinetics and tolerability of a new putative non‐benzodiazepine type anxiolytic compound deramciclane was studied in… 
1999
1999
Pharmacokinetics and safety of deramciclane during multiple oral dosing.
UNLABELLED Deramciclane is a new putative non-benzodiazepine-type anxiolytic compound. It is a selective serotonin 5-HT(2A) and 5… 
1998
1998
Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation
Abstract Deramciclane (EGIS-3886) is a novel anxiolytic agent that binds with high affinity to 5-HT2A/2C receptors. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)